Conjugates of Small Molecule Drugs with Antibodies and Other Proteins

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2017 May 27

PMID 28548057

Citations 12

Authors

Yang Feng

Zhongyu Zhu

Weizao Chen

Ponraj Prabakaran

Kedan Lin

Dimiter S Dimitrov

Affiliations

Soon will be listed here.

Abstract

Conjugates of small molecule drugs with antibodies (ADCs) and with other proteins (protein-drug conjugates, PDC) are used as a new class of targeted therapeutics combining the specificity of monoclonal antibodies (mAbs) and other proteins with potent cytotoxic activity of small molecule drugs for the treatment of cancer and other diseases. A(P)DCs have three major components, antibody (targeting protein), linker and payload, the cytotoxic drug. Recently, advances in identifying targets, selecting highly specific mAbs of preferred isotypes, optimizing linker technology and improving chemical methods for conjugation have led to the approval of two ADCs by Food and Drug Administration (FDA) and more than 30 ADCs in advanced clinical development. However, the complex and heterogeneous nature of A(P)DCs often cause poor solubility, instability, aggregation and eventually unwanted toxicity. This article reviews the main components of A(P)DCs, and discusses the choices for drugs, linkers and conjugation methods currently used. Future work will need to focus on developments and strategies for overcoming such major problems associated with the A(P)DCs.

Citing Articles

Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development.

Dave B, Shah Y, Maheshwari K, Mansuri K, Prajapati B, Postwala H Cell Mol Neurobiol. 2023; 43(8):3847-3884.

PMID: 37725199 PMC: 11407742. DOI: 10.1007/s10571-023-01408-7.

Site-Specific Antibody Conjugation Using Modified Bisected -Glycans: Method Development and Potential toward Tunable Effector Function.

Hsu Y, Nourzaie O, Tocher A, Nerella K, Ermakov G, Jung J Bioconjug Chem. 2023; 34(9):1633-1644.

PMID: 37620302 PMC: 10516122. DOI: 10.1021/acs.bioconjchem.3c00302.

Smart Nanozymes for Cancer Therapy: The Next Frontier in Oncology.

P N N, Mehla S, Begum A, Chaturvedi H, Ojha R, Hartinger C Adv Healthc Mater. 2023; 12(25):e2300768.

PMID: 37392379 PMC: 11481082. DOI: 10.1002/adhm.202300768.

Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.

Maiti R, Patel B, Patel N, Patel M, Patel A, Dhanesha N Arch Pharm Res. 2023; 46(5):361-388.

PMID: 37071273 PMC: 11345756. DOI: 10.1007/s12272-023-01447-0.

Simple, Rapid Chemical Labeling and Screening of Antibodies with Luminescent Peptides.

Kincaid V, Wang H, Sondgeroth C, Torio E, Ressler V, Fitzgerald C ACS Chem Biol. 2022; 17(8):2179-2187.

PMID: 35862857 PMC: 9396617. DOI: 10.1021/acschembio.2c00306.

References

Mullard A . Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013; 12(5):329-32. DOI: 10.1038/nrd4009. View

Kulkarni P, Blair A, Ghose T, Mammen M . Conjugation of methotrexate to IgG antibodies and their F(ab)2 fragments and the effect of conjugated methotrexate on tumor growth in vivo. Cancer Immunol Immunother. 1985; 19(3):211-4. PMC: 11039069. DOI: 10.1007/BF00199228. View

Ramakrishnan B, Boeggeman E, Manzoni M, Zhu Z, Loomis K, Puri A . Multiple site-specific in vitro labeling of single-chain antibody. Bioconjug Chem. 2009; 20(7):1383-9. PMC: 3402211. DOI: 10.1021/bc900149r. View

Perez H, Cardarelli P, Deshpande S, Gangwar S, Schroeder G, Vite G . Antibody-drug conjugates: current status and future directions. Drug Discov Today. 2013; 19(7):869-81. DOI: 10.1016/j.drudis.2013.11.004. View

Chen W, Zhu Z, Feng Y, Dimitrov D . Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A. 2008; 105(44):17121-6. PMC: 2579388. DOI: 10.1073/pnas.0805297105. View

Ma D, Hopf C, Malewicz A, Donovan G, Senter P, Goeckeler W . Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res. 2006; 12(8):2591-6. DOI: 10.1158/1078-0432.CCR-05-2107. View

. Why is it so difficult to use gemtuzumab ozogamicin?. Blood. 2013; 121(24):4813-4. DOI: 10.1182/blood-2013-05-498683. View

Hollander I, Kunz A, Hamann P . Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. Bioconjug Chem. 2007; 19(1):358-61. DOI: 10.1021/bc700321z. View

Fayad L, Offner F, Smith M, Verhoef G, Johnson P, Kaufman J . Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol. 2013; 31(5):573-83. PMC: 4878046. DOI: 10.1200/JCO.2012.42.7211. View

10.

Kokai Y, Cohen J, Drebin J, Greene M . Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A. 1987; 84(23):8498-501. PMC: 299571. DOI: 10.1073/pnas.84.23.8498. View

11.

Koenig J, Edwardson J . Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci. 1997; 18(8):276-87. DOI: 10.1016/s0165-6147(97)01091-2. View

12.

Wang L, Amphlett G, Blattler W, Lambert J, Zhang W . Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci. 2005; 14(9):2436-46. PMC: 2253466. DOI: 10.1110/ps.051478705. View

13.

Flygare J, Pillow T, Aristoff P . Antibody-drug conjugates for the treatment of cancer. Chem Biol Drug Des. 2012; 81(1):113-21. DOI: 10.1111/cbdd.12085. View

14.

Remillard S, REBHUN L, Howie G, Kupchan S . Antimitotic activity of the potent tumor inhibitor maytansine. Science. 1975; 189(4207):1002-5. DOI: 10.1126/science.1241159. View

15.

Bindon C, Hale G, Bruggemann M, Waldmann H . Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q. J Exp Med. 1988; 168(1):127-42. PMC: 2188986. DOI: 10.1084/jem.168.1.127. View

16.

Doronina S, Bovee T, Meyer D, Miyamoto J, Anderson M, Morris-Tilden C . Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem. 2008; 19(10):1960-3. DOI: 10.1021/bc800289a. View

17.

Litvak-Greenfeld D, Benhar I . Risks and untoward toxicities of antibody-based immunoconjugates. Adv Drug Deliv Rev. 2012; 64(15):1782-99. DOI: 10.1016/j.addr.2012.05.013. View

18.

Naumovski L, Junutula J . Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010; 12(2):248-57. View

19.

Ritchie M, Tchistiakova L, Scott N . Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2012; 5(1):13-21. PMC: 3564878. DOI: 10.4161/mabs.22854. View

20.

Dumontet C, Jordan M . Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010; 9(10):790-803. PMC: 3194401. DOI: 10.1038/nrd3253. View